Adage Capital Partners’s Royalty Pharma RPRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $216M | Sell |
6,000,000
-250,000
| -4% | -$9.01M | 0.36% | 43 |
|
|
2025
Q1 | $195M | Sell |
6,250,000
-10,718,321
| -63% | -$334M | 0.36% | 49 |
|
|
2024
Q4 | $433M | Buy |
16,968,321
+5,069,127
| +43% | +$129M | 0.76% | 18 |
|
|
2024
Q3 | $337M | Buy |
11,899,194
+967,263
| +9% | +$27.4M | 0.59% | 23 |
|
|
2024
Q2 | $288M | Buy |
10,931,931
+115,000
| +1% | +$3.03M | 0.53% | 24 |
|
|
2024
Q1 | $329M | Sell |
10,816,931
-80,000
| -0.7% | -$2.43M | 0.62% | 24 |
|
|
2023
Q4 | $306M | Buy |
10,896,931
+1,056,931
| +11% | +$29.7M | 0.63% | 23 |
|
|
2023
Q3 | $267M | Buy |
9,840,000
+1,190,000
| +14% | +$32.3M | 0.61% | 24 |
|
|
2023
Q2 | $266M | Buy |
8,650,000
+1,405,133
| +19% | +$43.2M | 0.58% | 24 |
|
|
2023
Q1 | $261M | Buy |
7,244,867
+244,867
| +3% | +$8.82M | 0.59% | 24 |
|
|
2022
Q4 | $277M | Sell |
7,000,000
-1,165,000
| -14% | -$46M | 0.66% | 19 |
|
|
2022
Q3 | $328M | Sell |
8,165,000
-8,542,815
| -51% | -$343M | 0.81% | 12 |
|
|
2022
Q2 | $702M | Sell |
16,707,815
-8,134,900
| -33% | -$342M | 1.61% | 4 |
|
|
2022
Q1 | $968M | Hold |
24,842,715
| – | – | 1.84% | 4 |
|
|
2021
Q4 | $990M | Buy |
24,842,715
+144,900
| +0.6% | +$5.77M | 1.78% | 4 |
|
|
2021
Q3 | $893M | Buy |
24,697,815
+1,976,000
| +9% | +$71.4M | 1.76% | 4 |
|
|
2021
Q2 | $931M | Sell |
22,721,815
-1,965,941
| -8% | -$80.6M | 1.82% | 5 |
|
|
2021
Q1 | $1.08B | Sell |
24,687,756
-14,026,524
| -36% | -$612M | 2.2% | 4 |
|
|
2020
Q4 | $1.94B | Sell |
38,714,280
-7,301,050
| -16% | -$365M | 4.22% | 2 |
|
|
2020
Q3 | $1.94B | Hold |
46,015,330
| – | – | 4.85% | 2 |
|
|
2020
Q2 | $2.23B | Buy |
+46,015,330
| New | +$2.23B | 5.72% | 1 |
|